Wegovy in Sweden — price, dosage, side effects and results

01 Mar

Wegovy is the first drug with semaglutide officially approved for weight loss in Europe. Since the launch, interest has exploded — search pressure in Sweden has multiplied in just one year. But how much does the treatment actually cost? How do you dose correctly? And what side effects should you be prepared for? We break down everything you need to know before you decide.

This is how Wegovy works — semaglutide against obesity

Wegovy contains semaglutide at a dose of 2.4 mg per week, the same active substance found in Ozempic. The difference is the indication: Ozempic is approved for type 2 diabetes, while Wegovy specifically targets overweight and obesity. The dose in Wegovy is also higher — 2.4 mg compared to Ozempic’s maximum of 1 mg.

Semaglutide belongs to the group of GLP-1 receptor agonists. It mimics the natural gut hormone GLP-1 that is released after a meal. The effect is threefold: appetite is suppressed via signals to the brain’s satiety center, gastric emptying is slowed down so that food stays longer in the stomach, and insulin release is optimized in case of elevated blood sugar.

In practice, most users notice a clear difference already after two to three weeks. Feelings of hunger subside, portion sizes naturally decrease and cravings for fast carbohydrates and fatty foods become weaker. Many describe it as quieting the constant “background noise” of hunger — you just don’t think about food as often.

That mechanism makes Wegovy one of the most effective weight loss preparations on the market — provided the treatment is combined with changes in diet and exercise habits. Semaglutide makes it easier to maintain a caloric deficit, but it doesn’t do the job alone.

Wegovy dosage — escalation and number of clicks

The dosage of Wegovy follows a strict escalation schedule that extends over 16 weeks. The purpose of the gradual increase is to minimize gastrointestinal side effects and give the body time to adapt to the substance.

|Period|Dose per week|Click per dose|

|Weeks 1–4|0.25 mg|6 clicks|

|Weeks 5–8|0.5 mg|12 clicks|

|Week 9–12|1.0 mg|24 clicks|

|Week 13–16|1.7 mg|40 clicks|

|Week 17+|2.4 mg|56 clicks|

Each pen is pre-filled and intended for a specific dose — so you cannot use a 0.25 mg pen to take 0.5 mg. The injection is given subcutaneously in the abdomen, thigh or upper arm, once a week, preferably on the same day of the week. The time of day does not matter and the dose can be taken regardless of meals.

What do you do if you miss a dose?

Has it been less than five days since the scheduled dose? Take the injection as soon as you remember. Has it been more than five days? Skip the missed dose completely and take the next dose as usual on your regular day. Never double the dose to compensate.

Wegovy side effects — common and serious

The side effect profile of Wegovy is similar to other GLP-1 drugs, but the 2.4 mg dose — the highest approved for semaglutide — means a slightly higher proportion of users experience gastrointestinal distress compared to lower doses. The good news: most side effects are transient and concentrated in the escalation phase.

The most common side effects from the STEP studies:

• Nausea — reported by about 44% during the ramp-up phase, subsides significantly after 8-12 weeks

• Diarrhea — affects approximately 30% and is usually milder in intensity

• Constipation — occurs in approximately 24% and may require increased fiber intake or laxatives

• Vomiting — about 24% experienced this, mostly associated with dose escalation

• Headache and fatigue — most common in the first few weeks

Rare but serious side effects

Pancreatitis (inflammation of the pancreas) has been reported in isolated cases. Symptoms include severe, persistent pain in the upper abdomen that radiates to the back. Gallbladder problems, including gallstones, also occur to a somewhat increased degree in users who lose weight rapidly — however, this applies to all rapid weight loss, not just drug-assisted.

In 2025, the European Medicines Agency (EMA) added non-arterial anterior ischemic optic neuropathy (NAION) — an eye disease that can cause sudden vision loss — as a possible side effect for semaglutide preparations. The risk is very low, but people with diabetes should pay particular attention to vision changes during treatment.

Between 5 and 7% of participants in the clinical trials discontinued treatment due to side effects. This means that an overwhelming majority — over 93% — were able to complete despite initial discomfort.

Wegovy price in Sweden — cost with and without subsidy

The price issue determines for many whether Wegovy is a realistic alternative at all. The situation in Sweden is divided depending on your diagnosis.

For patients with type 2 diabetes, Wegovy can in theory be subsidized via the drug benefit, but the preparation is primarily intended for weight loss. In practice, most doctors prescribe Ozempic (with the same substance, lower dose) for diabetes. Wegovy is mainly printed for obesity — and then the cost is often borne by the patient.

Without subsidy, Wegovy in Sweden costs between SEK 3,500 and 5,500 per month, depending on the dose. During the ramp-up phase (the first 16 weeks), the cost is lower because the doses are smaller. At the full maintenance dose (2.4 mg), the monthly cost ends up in the upper range. If we count on a full year of treatment, the total cost comes to approximately SEK 50,000–65,000 without benefits — a sum that for many requires careful budgeting.

There are currently no generic versions of Wegovy approved in Europe. Novo Nordisk’s patent protects the product until then, and price competition remains limited. However, semaglutide in peptide form — without a pre-filled pen — is available as a research peptide and offers an affordable alternative to the established brands for those experienced with subcutaneous injections.

Wego view results — what do the studies and reality show?

The STEP 1 study, the largest clinical trial for Wegovy, followed over 1,900 participants without diabetes for 68 weeks. The group receiving semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. Almost a third of the participants achieved over 20% weight loss.

STEP 2 focused on patients with type 2 diabetes — a group where weight loss is generally more difficult to achieve. Even so, the average weight loss was 9.6% in 68 weeks, surpassing all previous GLP-1 preparations at that time.

What does it look like in reality outside of studies? Clinical experience shows that the results agree relatively well, but with an important caveat: participants in studies receive structured follow-up, dietary advice and regular check-ups. Outside of that environment, some users fall back into old eating habits, especially during stressful periods. Without that kind of professional support, realistic weight loss for most people is 10-15% in the first year — still a significant improvement that can lower blood pressure, blood lipids, and cardiovascular disease risk markers.

A central question is what happens after the end of treatment. The STEP 4 study investigated just this and found that participants who switched to placebo after 20 weeks regained about two-thirds of the weight lost within the following year. It emphasizes that Wegovy is not a one-time treatment but rather a long-term tool. If you combine it with lasting changes in diet and physical activity, the chances of maintaining the results increase — but without pharmacological support, most lose parts of their success. It is one factor that separates weight loss injections from more permanent procedures such as bariatric surgery.

Thinking about the differences between Wegovy and newer options like tirzepatid? We have a separate review of Mounjaro (tirzepatid) comparing efficacy, price and side effect profile.

.entry-content